Plasma cell neoplasm
diseaseOn this page
Also known as plasma cell dyscrasiaplasma cell tumorplasma cell tumor, malignantplasmacytic neoplasmplasmacytic tumorplasmacytic tumour
Summary
Plasma cell neoplasm (MONDO:0004959) is a cancer (an umbrella term covering 7 Mondo subtypes) and 40 clinical trials. Top therapeutic interventions include dexamethasone, allopurinol, and cefepime hydrochloride. A subtype of neoplasm of mature B-cells — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 7 Mondo subtypes
- Clinical trials: 40
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | plasma cell neoplasm |
| Mondo ID | MONDO:0004959 |
| EFO | EFO:0000200 |
| MeSH | D054219 |
| Orphanet | 98282 |
| DOID | DOID:6536 |
| NCIT | C4665 |
| SNOMED CT | 415111003 |
| UMLS | C1959632 |
| MedGen | 368758 |
| GARD | 0019440 |
| Is cancer (heuristic) | yes |
Also known as: plasma cell dyscrasia · plasma cell neoplasm · plasma cell tumor · plasma cell tumor, malignant · plasmacytic neoplasm · plasmacytic tumor · plasmacytic tumour
Disease family
This is a subtype of neoplasm of mature B-cells. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › immune system disorder › leukocyte disorder › B-cell neoplasm › neoplasm of mature B-cells › plasma cell neoplasm
Related subtypes (7): primary central nervous system lymphoma, B-cell chronic lymphocytic leukemia, Burkitt lymphoma, MALT lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, B-cell prolymphocytic leukemia
Subtypes (7): refractory plasma cell neoplasm, plasmacytoma, leukemoid reaction, plasma cell myeloma, plasma cell leukemia, non-amyloid monoclonal immunoglobulin deposition disease, heavy chain disease
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
1 approved, 10 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Idecabtagene Vicleucel | Approved (phase 4) |
| Dexamethasone | Phase 3 (in late-stage trials) |
| Filgrastim | Phase 3 (in late-stage trials) |
| Idarubicin | Phase 3 (in late-stage trials) |
| Lenalidomide | Phase 3 (in late-stage trials) |
| Lomustine | Phase 3 (in late-stage trials) |
| Melphalan | Phase 3 (in late-stage trials) |
| Prednisolone | Phase 3 (in late-stage trials) |
| Prednisone | Phase 3 (in late-stage trials) |
| Thalidomide | Phase 3 (in late-stage trials) |
| Valspodar | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Arsenic Trioxide, Ascorbic Acid, Bevacizumab, Bortezomib, Busulfan, Carmustine, Cyclosporine, Cytarabine, Daclizumab, Doxorubicin, Epigalocatechin Gallate, Etoposide, Fludarabine Phosphate, Hydrocortisone, Interferon Alfa, Methotrexate, Methylprednisolone, Mycophenolate Mofetil, Oblimersen Sodium, Pegfilgrastim, Pomalidomide, Rituximab, Sargramostim, Semaxanib, Tacrolimus Anhydrous, Thiotepa.
Clinical trials & evidence
Clinical trials
Clinical trials: 40.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 15 |
| PHASE1 | 10 |
| PHASE2 | 7 |
| PHASE1/PHASE2 | 4 |
| EARLY_PHASE1 | 2 |
| PHASE4 | 1 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04080531 | PHASE4 | COMPLETED | Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders |
| NCT00064038 | PHASE3 | COMPLETED | S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma |
| NCT05336383 | PHASE2 | RECRUITING | Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma |
| NCT00028600 | PHASE2 | COMPLETED | Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma |
| NCT00048412 | PHASE1/PHASE2 | COMPLETED | Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H |
| NCT00053196 | PHASE2 | COMPLETED | Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer |
| NCT00075608 | PHASE2 | TERMINATED | 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis |
| NCT00303719 | PHASE2 | TERMINATED | Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy |
| NCT00547365 | PHASE1/PHASE2 | COMPLETED | Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction |
| NCT00579111 | PHASE1/PHASE2 | TERMINATED | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) |
| NCT00790842 | PHASE1/PHASE2 | TERMINATED | Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction |
| NCT01350245 | PHASE2 | COMPLETED | Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor |
| NCT02556931 | PHASE2 | COMPLETED | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies |
| NCT00005792 | PHASE1 | COMPLETED | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma |
| NCT00602693 | PHASE1 | COMPLETED | T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer |
| NCT00729118 | PHASE1 | COMPLETED | Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma |
| NCT00890747 | PHASE1 | COMPLETED | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy |
| NCT00891137 | PHASE1 | COMPLETED | Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy |
| NCT01219010 | PHASE1 | COMPLETED | A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma |
| NCT01484015 | PHASE1 | COMPLETED | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia |
| NCT03999697 | PHASE1 | UNKNOWN | A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies |
| NCT04354246 | PHASE1 | COMPLETED | COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies |
| NCT05350163 | PHASE1 | TERMINATED | T-cell Receptor α/β Depleted Donor Lymphocyte Infusion |
| NCT07365059 | EARLY_PHASE1 | NOT_YET_RECRUITING | Safety and Efficacy of GPRC5D CAR-T Cell Therapy in Relapsed/Refractory Plasma Cell Disorders |
| NCT07586709 | EARLY_PHASE1 | NOT_YET_RECRUITING | In Vivo BCMA/GPRC5D Tandem Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell Neoplasms |
| NCT01408225 | Not specified | RECRUITING | Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource |
| NCT02012699 | Not specified | RECRUITING | Integrated Cancer Repository for Cancer Research |
| NCT02671448 | Not specified | RECRUITING | Pilot Trial of Homebound Stem Cell Transplantation |
| NCT03616483 | Not specified | RECRUITING | The Indiana Myeloma Registry |
| NCT04210791 | Not specified | ENROLLING_BY_INVITATION | Autologous Stem Cell Transplantation for Patients With AL Amyloidosis |
| NCT00118339 | Not specified | COMPLETED | Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma |
| NCT00400686 | Not specified | COMPLETED | Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma |
| NCT00536601 | Not specified | COMPLETED | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors |
| NCT00874211 | Not specified | COMPLETED | S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases |
| NCT01132833 | Not specified | COMPLETED | Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy |
| NCT01186224 | Not specified | COMPLETED | Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC) |
| NCT01558778 | Not specified | WITHDRAWN | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant |
| NCT02741999 | Not specified | COMPLETED | A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early |
| NCT04665076 | Not specified | UNKNOWN | Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors |
| NCT05362331 | Not specified | WITHDRAWN | Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DEXAMETHASONE | 4 | 2 |
| ALLOPURINOL | 4 | 1 |
| CEFEPIME HYDROCHLORIDE | 4 | 1 |
| ETOPOSIDE PHOSPHATE | 4 | 1 |
| LENALIDOMIDE | 4 | 1 |
| SILTUXIMAB | 4 | 1 |
| COM-701 | 1 | 1 |
| CHEMBL1201736 | 0 | 1 |